Steven P. Rowe

Dr. Steven P. Rowe

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2021 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
PDF file
SRSteven P. Rowe
Steven P. Rowe
MPMartin Pomper
Martin Pomper
The authors define molecular imaging, according to the Society of Nuclear Medicine and Molecular Imaging, as the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in humans and other living systems. Although practiced for many years clinically in nuclear medicine, expansion to other imaging modalities began roughly 25 years ago and has accelerated since. That acceleration derives from the continual appearance of new and highly relevant animal models of human disease, increasingly sensitive imaging devices, high‐throughput methods to discover and optimize affinity agents to key cellular targets, new ways to manipulate genetic material, and expanded use of cloud computing. Greater interest by scientists in allied fields, such as chemistry, biomedical engineering, and immunology, as well as increased attention by the pharmaceutical industry, have likewise contributed to the boom in activity in recent years. Whereas researchers and clinicians have applied molecular imaging to a variety of physiologic processes and disease states, here, the authors focus on oncology, arguably where it has made its greatest impact. The main purpose of imaging in oncology is early detection to enable interception if not prevention of full‐blown disease, such as the appearance of metastases. Because biochemical changes occur before changes in anatomy, molecular imaging—particularly when combined with liquid biopsy for screening purposes—promises especially early localization of disease for optimum management. Here, the authors introduce the ways and indications in which molecular imaging can be undertaken, the tools used and under development, and near‐term challenges and opportunities in oncology.

1 August 2017 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
SSSara Sheikhbahaei
Sara Sheikhbahaei
AAAli Afshar-Oromieh
Ali Afshar-Oromieh
MEMatthias Eiber
Matthias Eiber
LSLilja B. Solnes
Lilja B. Solnes
MJMehrbod S. Javadi
Mehrbod S. Javadi
SRSteven P. Rowe
Steven P. Rowe

8 September 2017 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
SRSteven P. Rowe
Steven P. Rowe
KPKenneth J. Pienta
Kenneth J. Pienta
MPMartin G. Pomper
Martin G. Pomper
MGMichael A. Gorin
Michael A. Gorin
As medical imaging has grown progressively more complicated and subspecialized in recent decades, several standardized reporting systems have been proposed for a variety of imaging modalities and conditions. These include reporting and data systems for imaging of the breast (BI-RADS) (1), prostate (PI-RADS) (2), lung (LUNG-RADS) (3), liver (LI-RADS) (4), and thyroid (TI-RADS) (5). Although these systems differ extensively in their details, each provides a standardized framework for conveying findings and recommendations to clinicians. Within the field of molecular imaging, efforts at instituting standardized reporting systems have been largely focused on response to therapy, such as the Lugano criteria (6). Among the wide array of molecular agents that have been developed for imaging prostate cancer (PCa), perhaps the most exciting results have been generated with the urea-based small molecules targeting the active site of prostate-specific membrane antigen (PSMA) (7-9). Labeled with radionuclides that allow for PET, such agents have been investigated in the context of preoperative staging of patients at risk of occult pelvic lymph node involvement (10), patients found to have biochemical recurrence after definitive therapy (11,12), and patients with widely metastatic disease (13). Overall, PSMA-targeted PET radiotracers have been found in the aforementioned studies, as well as in many others, to have high sensitivity and specificity for the identification of sites of PCa. Despite the outstanding performance characteristics noted in the literature, radiotracers targeting PSMA have been reported to show uptake in a number of nonprostatic malignancies (14-24), as well as in many types of benign lesions (25-40). Moreover, even among sites of PCa, the degree of uptake can vary widely depending on the level of PSMA expression and the size and location of detected lesions. This implies a need for a standardized method by which imaging specialists interpreting

15 March 2018 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
RFRoberto A. Salas Fragomeni
Roberto A. Salas Fragomeni
TATali Amir
Tali Amir
SSSara Sheikhbahaei
Sara Sheikhbahaei
SHSusan C. Harvey
Susan C. Harvey
MJMehrbod S. Javadi
Mehrbod S. Javadi
SRSteven P. Rowe
Steven P. Rowe
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is highly overexpressed on prostate cancer epithelial cells and for which there is a growing body of literature examining the role of small-molecule and antibody radiotracers targeted against this protein for prostate cancer detection and therapy. Despite its name, PSMA is also expressed, to varying degrees, in the neovasculature of a wide variety of nonprostate cancers; indeed, the pathology literature is replete with promising immunohistochemistry findings. Several groups have begun to correlate those pathology-level results with in vivo imaging and therapy in nonprostate cancers using the same PSMA-targeted agents that have been so successful in prostate cancer. The potential to leverage radiotracers targeted to PSMA beyond prostate cancer is a promising approach for many cancers, and PSMA-targeted agents may be able to supplement or fill gaps left by other agents. However, to date, most of the reported findings with PSMA-targeted radiotracers in nonprostate malignancies have been in case reports and small case series, and the field must adopt a more thorough approach to the design and execution of larger prospective trials to realize the potential of these promising agents outside prostate cancer.

1 April 2018 in European Urology
Verified
Journal Article
Closed access
SRSteven P. Rowe
Steven P. Rowe
KPKenneth J. Pienta
Kenneth J. Pienta
MPMartin G. Pomper
Martin G. Pomper
MGMichael A. Gorin
Michael A. Gorin

1 July 2023 in Radiology
Verified
Journal Article
Closed access
AGAndrei Gafita
Andrei Gafita
LDLoïc Djaileb
Loïc Djaileb
IRIsabel Rauscher
Isabel Rauscher
WFWolfgang P. Fendler
Wolfgang P. Fendler
BHBoris Hadaschik
Boris Hadaschik
AFAndrea Farolfi
Andrea Farolfi
Background Response Evaluation Criteria in Prostate-specific Membrane Antigen (PSMA) PET/CT (RECIP 1.0) initially integrated software-based quantitative assessment of PSMA-positive total tumor volume (TTV). Clinical implementation of such software is not expected soon, limiting the use of RECIP in practice. Purpose To assess the agreement of RECIP determined using tumor segmentation software (quantitative RECIP) with RECIP determined by qualitative reads by nuclear medicine physicians (visual RECIP) for response evaluation in metastatic castration-resistant prostate cancer. Materials and Methods This multicenter retrospective study at three academic centers included men who received lutetium 177 (177Lu) PSMA treatment between December 2014 and July 2019. PSMA PET/CT images at baseline and 12 weeks were assessed qualitatively by five readers for changes in TTV and for new lesions. Quantitative changes in TTV were also measured using tumor segmentation software. The status of new lesions was combined with qualitative changes in TTV to determine visual RECIP and with quantitative changes in TTV to determine quantitative RECIP. The primary outcomes were the agreement between visual and quantitative RECIP and the interreader reliability of visual RECIP according to the Fleiss κ. The secondary outcome was the association of visual RECIP with overall survival according to Cox regression. Results A total of 124 men (median age, 73 years [IQR, 67-76 years]) were included. Forty (32%) and 84 (68%) men had quantitative RECIP progressive disease (PD) and non-PD, respectively. Agreement between visual versus quantitative RECIP was excellent (κ = 0.89; 118 of 124 men [95%]). Agreement among readers in classifying visual RECIP PD versus non-PD was excellent (κ = 0.81; 103 of 124 men [83%]). RECIP PD was associated with significantly shorter overall survival compared with non-PD (hazard ratio, 2.6 [95% CI: 1.7, 3.8]; P < .001). Conclusion Qualitatively assessed RECIP demonstrated excellent agreement with quantitative RECIP and excellent interreader reliability and can be readily implemented in clinical practice for response evaluation in men with metastatic castration-resistant prostate cancer undergoing 177Lu-PSMA therapy. © RSNA, 2023 Supplemental material is available for this article.